CSI Market
Sign In | Register

Anavex Life Sciences (AVXL) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access AVXL Annual Cash Flow →
The quarterly cash flow data below helps track how Anavex Life Sciences's liquidity profile has evolved over recent quarters.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
9 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-6.37
Depreciation & amortization0.00
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.19
Income (Loss) from Equity Method Investments0.00
Foreign Currency Transaction Gain (Loss), Unrealized0.05
Common Shares Issued For Severance-
Common Shares Issued For Research And Development Expenses-
Labor And Related Expense-
Other Nonoperating Expense-
Gain Loss On Settlement Of Accounts Payable-
Non Cash Financing Related Charges-
Noncash Financing Related Charges-
Embedded Derivative Gain Loss On Embedded Derivative Net-
Gain On Settlement Of Accounts Payable-
Deferred Charges-
Deferred Grant Income-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Income Taxes Receivable0.19
Increase (Decrease) in Accounts Payable-0.59
Increase (Decrease) in Accrued Liabilities-0.66
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense0.39
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-13.87
Discontinued operations0.00
Net Cash flow from Operating Activities-20.69
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.01
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net36.43
Proceeds From Share Subscriptions Received-
Proceeds From Shareholder Advances-
Shares Subscribed-
Issuance Of Common Shares-
Issuance Of Common Shares Net Of Share Issue Costs36.32
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities36.44
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-20.69
Total Cash Flow15.75
4 historic quarters locked

Sign in to unlock the full Anavex Life Sciences cash flow history.

Sign In Create Free Account

About Anavex Life Sciences Corp Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20260630)
  • Filed with the SEC: August 28, 2026
  • Source: e7886_10-q.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001731122-26-001167

Figures are derived from filed reports and may be restated. Historical data is subject to revision.